Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials
Abstract
Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long‐term survival. In the mid‐1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5‐fluorouracil‐based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further...
Paper Details
Title
Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials
Published Date
Apr 8, 2021
Journal
Volume
123
Issue
6
Pages
1467 - 1474
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History